13 · Where this brief could be wrong
Where this brief could be wrong
Bookmarks need a Mind Club sign-in. How sign-in works
Where this brief could be wrong across your briefsOur biggest conclusion, the strongest case against it, and what would settle it.
RED TEAM
Base case. Pan-RAS drugs are moving toward first-line pancreatic cancer, on single-arm data. Analysis
Counter-case. Response rates in small, selected groups often shrink in randomized trials, and adding a drug that also blocks normal RAS to chemotherapy may cost tolerability that a short single-arm study does not show.
What would settle it. RASolute 303’s survival comparison against chemotherapy alone, and full safety tables for both drugs.
| Consensus | Counter-case | What would settle it |
|---|---|---|
| Xanamem may still work in older patients | The subgroup came after a missed primary, and its mean slowing was not significant | A new trial in older patients with that as its primary |
| Sanofi may bid for Insmed | The report cites unnamed sources and no price; companies weigh many deals they never make | An announcement by either company |
BLIND SPOT CHECK
GlobeNewswire’s search and the Business Wire newsroom did not load, so wire coverage was partial. We read Revolution’s release through Investing News, Alnylam’s through Yahoo Finance and Actinogen’s through BioSpace, and read DISCO’s release through Yahoo Finance. The Insmed report is secondhand, the CME FedWatch reading comes through a newsletter, and the Insmed report has no public primary copy. ClinicalTrials.gov, Open Targets, ChEMBL and PubMed were reached through their connectors. Early European and Asian releases may be missing.